ImmunityBio, Inc. (IBRX)
IBRX moved a median of +0.07% 30 minutes after news, and -0.14% by the close. How IBRX actually reacts to news — the realized, point-in-time move the market made, measured across 869 labeled events over the last three years with zero look-ahead.
IBRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.06% | 52% | 866 |
| 30-min | +0.07% | 51% | 867 |
| 60-min | +0.07% | 52% | 867 |
| to close | -0.14% | 45% | 865 |
| Middle 50% of IBRX reactions | -1.80% to +2.06% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 869 |
Half of all ImmunityBio, Inc. news events land between -1.80% and +2.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IBRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IBRX's baseline. Nothing else.
Recent IBRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors | Press release | Business Wire | -0.32% | -2.18% | |
| ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.05% | -0.84% | |
| FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease | Press release | Business Wire | -1.62% | -1.96% | |
| Form 8-K ImmunityBio, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -1.96% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -2.04% | -4.08% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.26% | +1.59% | |
| ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium | Press release | Business Wire | -1.25% | +2.91% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.59% | +2.61% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.69% | +3.07% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.26% | -2.87% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.12% | -1.28% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.06% | -0.00% | |
| ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.13% | +2.83% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.13% | +1.02% | |
| ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.12% | -2.72% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.13% | +2.76% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.30% | -1.30% | |
| ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman | Press release | Business Wire | +1.40% | — | |
| Form 10-Q ImmunityBio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.20% | +2.51% | |
| Form 8-K ImmunityBio, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +6.20% | +2.51% | |
| ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million | Press release | Business Wire | +6.20% | +2.51% | |
| Form 8-K ImmunityBio, Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | -3.76% | |
| ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer | Press release | Business Wire | -1.04% | +3.19% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.28% | -3.05% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.80% | -1.79% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.19% | +3.33% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.67% | -2.03% | |
| ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.13% | +0.96% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.28% | +0.57% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.06% | +3.67% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.58% | -0.74% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.06% | +0.29% | |
| ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +7.31% | +5.16% | |
| Form 8-K ImmunityBio, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +2.86% | |
| ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | Press release | Business Wire | +2.20% | -0.48% | |
| ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS | Press release | GlobeNewswire | +3.27% | +8.79% | |
| ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS | Press release | PR Newswire | +3.27% | +8.79% | |
| ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation | Press release | Business Wire | -2.43% | -5.25% | |
| ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. | Press release | GlobeNewswire | +0.48% | +0.14% | |
| ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | Press release | Business Wire | -2.43% | -5.25% | |
| ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS | Press release | PR Newswire | -1.84% | -1.53% | |
| ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 | Press release | Business Wire | +0.65% | -4.39% | |
| ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 | Press release | Business Wire | -4.90% | -2.51% | |
| Form 8-K ImmunityBio, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -4.90% | -2.51% | |
| ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 | Press release | Business Wire | -2.15% | -4.54% | |
| ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States | Press release | Business Wire | -2.15% | -4.54% | |
| ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX | Press release | PR Newswire | -1.58% | -1.09% | |
| Form 10-Q ImmunityBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.73% | -0.51% | |
| Form 8-K ImmunityBio, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.73% | -0.51% | |
| IBRX Lawsuit Alleges Company Allegedly Violated FDA Drug Rules - ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallSt | Press release | PR Newswire | +1.73% | -0.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IBRX section they belong to.
Where else IBRX is measured.
IBRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ImmunityBio, Inc.'s median reaction calculated?
Every labeled IBRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 869 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of IBRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IBRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.